Skip to main content
Erschienen in: International Urology and Nephrology 3/2017

29.12.2016 | Urology - Original Paper

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach

verfasst von: Wolfgang Otto, Johannes Breyer, Sonja Herdegen, Fabian Eder, Simone Bertz, Matthias May, Roman Mayr, Eva M. Lausenmeyer, Stefan Denzinger, Bas W. G. van Rhijn, Maximilian Burger, Arndt Hartmann

Erschienen in: International Urology and Nephrology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial–mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC.

Methods

Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin. Kaplan–Meier analysis and univariate and multivariate Cox regression analyses regarding progression-free (PFS) and cancer-specific survival (CSS) were performed.

Results

Aberrant expression of E-cadherin was recognized in 74% of patients. Kaplan–Meier analysis showed that aberrant E-cadherin expression was associated with worse 10-year PFS (62 vs. 90%, p = 0.045). In univariate analysis, aberrant E-cadherin staining, associated carcinoma in situ, grading 3 after WHO classification 1973 and infiltrative growth pattern at the invasion front were the statistically significant predictive factors for worse PFS, only infiltrative growth pattern for CSS. With regard to progression, grading 3 after WHO classification of 1973 (HR 6.49; CI 1.54–27.28, p = 0.011) and infiltrative tumor invasion pattern (HR 2.06; CI 1.10–3.86, p = 0.024) revealed as independent factors for PFS, and there was a trend also for E-cadherin expression (HR 0.45; CI 0.19–1.06; p = 0.068). Regarding CSS, infiltrative tumor growth pattern (HR 3.79; CI 1.67–8.60, p = 0.001) was the only statistically significantly independent predictive factor in multivariate Cox regression analysis.

Conclusions

Beside invasion growth pattern and WHO grading 1973 that achieved to be independent prognostic factors, there was a trend for the parameter E-cadherin expression to be of predictive value for PFS in stage pT1 hg urothelial bladder carcinoma after organ-sparing approach. Further studies on genetic level are warranted to define the distinct role of EMT in early-invasive UBC.
Literatur
1.
Zurück zum Zitat Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19:294–308CrossRefPubMed Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19:294–308CrossRefPubMed
2.
Zurück zum Zitat Shook D, Keller R (2003) Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development. Mech Dev 120:1351–1383CrossRefPubMed Shook D, Keller R (2003) Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development. Mech Dev 120:1351–1383CrossRefPubMed
3.
Zurück zum Zitat Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6001CrossRefPubMed Tarin D (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6001CrossRefPubMed
4.
Zurück zum Zitat McConkey DJ, Lee S, Choi W et al (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumour initiation and progression. Urol Oncol Semin Invest 28:429–440CrossRef McConkey DJ, Lee S, Choi W et al (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumour initiation and progression. Urol Oncol Semin Invest 28:429–440CrossRef
5.
Zurück zum Zitat Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749CrossRefPubMed Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749CrossRefPubMed
6.
Zurück zum Zitat Spaderna S, Schmalhofer O, Hlubek F et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131(3):830–840CrossRefPubMed Spaderna S, Schmalhofer O, Hlubek F et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131(3):830–840CrossRefPubMed
7.
Zurück zum Zitat De Medina SG, Popov Z, Chopin DK et al (2008) Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene 18:5722–5726CrossRef De Medina SG, Popov Z, Chopin DK et al (2008) Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene 18:5722–5726CrossRef
8.
Zurück zum Zitat Byrne RR, Shariat SF, Brown R et al (2001) E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 165(5):1473–1479CrossRefPubMed Byrne RR, Shariat SF, Brown R et al (2001) E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 165(5):1473–1479CrossRefPubMed
9.
Zurück zum Zitat Baumgart E, Cohen MS, Silva Neto B et al (2007) Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 13(6):1685–1694CrossRefPubMed Baumgart E, Cohen MS, Silva Neto B et al (2007) Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 13(6):1685–1694CrossRefPubMed
10.
Zurück zum Zitat Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M (2012) Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 30(2):161–166CrossRefPubMed Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M (2012) Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 30(2):161–166CrossRefPubMed
11.
Zurück zum Zitat Clairotte A, Lascombe I, Fauconnet S, Kantelip B et al (2006) Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125(1):119–126CrossRefPubMed Clairotte A, Lascombe I, Fauconnet S, Kantelip B et al (2006) Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125(1):119–126CrossRefPubMed
12.
Zurück zum Zitat Moyano Calvo JL, Blanco Palenciano E, Beato Moreno A et al (2006) Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors. Actas Urol Esp 30(9):871–878CrossRefPubMed Moyano Calvo JL, Blanco Palenciano E, Beato Moreno A et al (2006) Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors. Actas Urol Esp 30(9):871–878CrossRefPubMed
13.
Zurück zum Zitat Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169(1):96–100 discussion 100 CrossRefPubMed Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169(1):96–100 discussion 100 CrossRefPubMed
14.
Zurück zum Zitat San Miguel Fraile P, Gómez de María C, Donis Quintairos L, Carrera Vazquez A, Iglesias Martínez P, Barreiro Barbosa MJ (2007) [Expression of E-cadherin and catenins in urothelial carcinomas]. Actas Urol Esp 31(4):355–360CrossRefPubMed San Miguel Fraile P, Gómez de María C, Donis Quintairos L, Carrera Vazquez A, Iglesias Martínez P, Barreiro Barbosa MJ (2007) [Expression of E-cadherin and catenins in urothelial carcinomas]. Actas Urol Esp 31(4):355–360CrossRefPubMed
15.
Zurück zum Zitat Jang TJ, Cha WH, Lee KS (2010) Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch 457(3):319–328CrossRefPubMed Jang TJ, Cha WH, Lee KS (2010) Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch 457(3):319–328CrossRefPubMed
16.
Zurück zum Zitat Hu X, Ruan Y, Cheng F, Yu W, Zhang X, Larré S (2011) p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol 18(9):630–637PubMed Hu X, Ruan Y, Cheng F, Yu W, Zhang X, Larré S (2011) p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol 18(9):630–637PubMed
17.
Zurück zum Zitat Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54:258–263CrossRefPubMed Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54:258–263CrossRefPubMed
18.
Zurück zum Zitat Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H (1998) Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34:67–72CrossRefPubMed Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H (1998) Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34:67–72CrossRefPubMed
19.
Zurück zum Zitat Orsola A, Trias I, Raventós CX et al (2005) Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48:231–238CrossRefPubMed Orsola A, Trias I, Raventós CX et al (2005) Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48:231–238CrossRefPubMed
20.
Zurück zum Zitat Denzinger S, Burger M, Fritsche HM et al (2009) Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol 43(4):282–287CrossRefPubMed Denzinger S, Burger M, Fritsche HM et al (2009) Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol 43(4):282–287CrossRefPubMed
21.
Zurück zum Zitat Brake M, Loertzer H, Horsch R, Keller H (2000) Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163:1697–1705CrossRefPubMed Brake M, Loertzer H, Horsch R, Keller H (2000) Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163:1697–1705CrossRefPubMed
22.
Zurück zum Zitat Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59:227–231CrossRefPubMed Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59:227–231CrossRefPubMed
23.
Zurück zum Zitat Bertz S, Denzinger S, Otto W et al (2011) Histomorphological parameters can improve risk stratification in pT1 urothelial bladder cancer—evaluation of a large (hospital-based) single-centre series. Histopathology 59(4):722–732CrossRefPubMed Bertz S, Denzinger S, Otto W et al (2011) Histomorphological parameters can improve risk stratification in pT1 urothelial bladder cancer—evaluation of a large (hospital-based) single-centre series. Histopathology 59(4):722–732CrossRefPubMed
24.
Zurück zum Zitat van Rhijn BW, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern t1 bladder cancer substage. Eur Urol 61(2):378–384CrossRefPubMed van Rhijn BW, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern t1 bladder cancer substage. Eur Urol 61(2):378–384CrossRefPubMed
25.
Zurück zum Zitat Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53(14):3241–3245PubMed Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53(14):3241–3245PubMed
26.
Zurück zum Zitat Kashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T (2007) The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 14(9):789–794CrossRefPubMed Kashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T (2007) The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 14(9):789–794CrossRefPubMed
27.
Zurück zum Zitat Bryan RT, Atherfold PA, Yeo Y et al (2008) Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 215(2):184–194CrossRefPubMed Bryan RT, Atherfold PA, Yeo Y et al (2008) Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 215(2):184–194CrossRefPubMed
28.
Zurück zum Zitat Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z (2008) E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int 81(3):320–324CrossRefPubMed Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z (2008) E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int 81(3):320–324CrossRefPubMed
29.
Zurück zum Zitat Otto W, Denzinger S, Fritsche HM et al (2011) The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 107(3):404–408CrossRefPubMed Otto W, Denzinger S, Fritsche HM et al (2011) The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 107(3):404–408CrossRefPubMed
Metadaten
Titel
WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach
verfasst von
Wolfgang Otto
Johannes Breyer
Sonja Herdegen
Fabian Eder
Simone Bertz
Matthias May
Roman Mayr
Eva M. Lausenmeyer
Stefan Denzinger
Bas W. G. van Rhijn
Maximilian Burger
Arndt Hartmann
Publikationsdatum
29.12.2016
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 3/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1491-9

Weitere Artikel der Ausgabe 3/2017

International Urology and Nephrology 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.